Voloshyna Diana, Sandhu Qudsia I, Khan Saima, Bseiso Anan, Mengar Jaina, Nayudu Nirupama, Kumar Rajesh, Khemani Deepa, Usama Muhammad
School of Medicine, University of Michigan, Ann Arbor, USA.
Medicine, Ghazi Khan Medical College, Dera Ghazi Khan, PAK.
Cureus. 2022 Sep 9;14(9):e28974. doi: 10.7759/cureus.28974. eCollection 2022 Sep.
Metformin remains the oral drug of choice for patients with type 2 diabetes mellitus (T2DM). It is an ideal anti-diabetic drug for maintaining good glycemic control in diabetics. However, the side effect profile of metformin varies from minor or no effects to substantial impact on the GI tract. In addition, metformin is rarely known for its association with nightmares. Here we present the case of a newly diagnosed 40-year-old diabetic who developed recurrent nightmares within a week of starting metformin treatment. The patient had no previous history of psychiatric or sleep disorders. However, it was the first time he had experienced such recurrent nightmares, especially after the start of 500 mg metformin thrice a day. Based on the Naranjo Adverse Drug Reaction (ADR) Probability Scale, and sudden onset and disappearance of nightmares after metformin initiation and discontinuation made metformin the primary cause of his nightmares.
二甲双胍仍然是2型糖尿病（T2DM）患者的口服首选药物。它是一种理想的抗糖尿病药物，可使糖尿病患者维持良好的血糖控制。然而，二甲双胍的副作用表现不一，从轻微或无影响到对胃肠道有重大影响。此外，二甲双胍很少因与噩梦有关而为人所知。在此，我们报告一例新诊断的40岁糖尿病患者，在开始二甲双胍治疗一周内出现反复噩梦的病例。该患者既往无精神或睡眠障碍病史。然而，这是他首次经历此类反复噩梦，尤其是在开始每日三次服用500毫克二甲双胍之后。根据纳伦霍药物不良反应（ADR）概率量表，以及二甲双胍开始和停用后噩梦的突然出现和消失，使二甲双胍成为其噩梦的主要原因。
